Abstract
The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress in the development of inhibitors of sulfur metabolism enzymes.
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design, inhibitors
Infectious Disorders - Drug Targets
Title: Drug Targets in Mycobacterial Sulfur Metabolism
Volume: 7 Issue: 2
Author(s): Devayani P. Bhave, Wilson B. Muse III and Kate S. Carroll
Affiliation:
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design, inhibitors
Abstract: The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress in the development of inhibitors of sulfur metabolism enzymes.
Export Options
About this article
Cite this article as:
Devayani P. Bhave , Wilson B. Muse III and Kate S. Carroll , Drug Targets in Mycobacterial Sulfur Metabolism, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001772
DOI https://dx.doi.org/10.2174/187152607781001772 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy General Theory for Multiple Input-Output Perturbations in Complex Molecular Systems. 1. Linear QSPR Electronegativity Models in Physical, Organic, and Medicinal Chemistry
Current Topics in Medicinal Chemistry p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Antimicrobial and Antifungal Properties of Leaves to Root Extracts and Saponin Fractions of <i>Chlorophytum borivilianum</i>
Current Bioactive Compounds Computer-Aided Design of a Novel Poly-Epitope Protein in Fusion with an Adjuvant as a Vaccine Candidate Against Leptospirosis
Current Proteomics Novel Compounds and Drugs and Recent Patents in Treating Multidrug- Resistant and Extensively Drug-Resistant Tuberculosis
Recent Patents on Anti-Infective Drug Discovery Population Pharmacokinetics and its Role in Anti-Tuberculosis Drug Development and Optimization of Treatment
Current Pharmaceutical Design Spices Chemoconstituents as Persuasive Inhibitor of S. typhimurium Virulent Protein L-asparaginase
Letters in Drug Design & Discovery Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Armed Imidazo [1,2-a] Pyrimidines (Pyridines): Evaluation of Antibacterial Activity
Letters in Drug Design & Discovery Selective Elevation of Circulating CCL2/MCP1 Levels in Patients with Longstanding Post-vaccinal Macrophagic Myofasciitis and ASIA
Current Medicinal Chemistry Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Electroporation Gene Therapy: New Developments In Vivo and In Vitro
Current Gene Therapy New Frontiers in the Therapy of Tuberculosis: Fighting with the Global Menace
Mini-Reviews in Medicinal Chemistry Mycobacterium tuberculosis Treatment Modalities and Recent Insights
Current Drug Delivery Use of Clays as Nanocarriers of First-Line Tuberculostatic Drugs
Current Drug Delivery Solid-Phase Synthesis in the Twenty-First Century
Mini-Reviews in Medicinal Chemistry Targeting Enzymes with Phosphonate-Based Inhibitors: Mimics of Tetrahedral Transition States and Stable Isosteric Analogues of Phosphates
Current Enzyme Inhibition